Navarro Bardón

1. National Institute on Drug Abuse. (2022). Fentanyl DrugFacts.

2. Volkow ND, McLellan AT. (2016). Opioid Abuse in Chronic Pain Misconceptions and Mitigation Strategies. N Engl J Med, 374(13), 1253-1263.

3. Ciccarone D. (2019). The triple wave epidemic: Supply and demand drivers of the US opioid overdose crisis. Int J Drug Policy, 71, 183-188.

4. Schug SA, Ting S. (2017). Fentanyl Formulations in the Management of Pain: An Update. Drugs, 77(7), 747-763.

5. Bohnert ASB, Ilgen MA. (2019). Understanding Links among Opioid Use, Overdose, and Suicide. N Engl J Med, 380(1), 71-79.

6. Moher D, et al. (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med, 6(7), e1000097.

7. Han B, et al. (2023). Trends in Prescription Opioid Use and Misuse: United States, 2015-2023. JAMA, 330(2), 160-170.

8. Chou R, et al. (2020). Long-term Opioid Therapy in Patients With Chronic Noncancer Pain: A Systematic Review and Meta-analysis. Ann Intern Med, 172(6), 390-400.

9. Johnson ET, et al. (2024). Risk of opioid use disorder in patients receiving long-term fentanyl therapy: A prospective cohort study. Pain, 165(1), 45-53.

10. Smith KL, et al. (2023). Fentanyl use and suicide attempts: A systematic review and meta-analysis. Addiction, 118(3), 456-468.

11. Garc.a MS, Mart.nez LR. (2023). Suicide attempts with fentanyl among psychiatric patients: A five-year review. Psychiatric Research and Clinical Practice, 15(2), 189-197.

12. Thompson RJ, et al. (2024). Long-term fentanyl use and risk of psychiatric disorders: A meta-analysis of longitudinal studies. Pain Medicine, 25(4), 412-425.

13. Chen YZ, et al. (2024). Community-based naloxone distribution programs and opioid overdose mortality: A nationwide analysis. Public Health Reports, 139(1), 55-63.

14. Volkow ND, et al. (2019). The opioid crisis: a comprehensive approach. Mol Psychiatry, 24(6), 845-846.

15. Voon P, et al. (2017). Pain as a risk factor for substance use: a qualitative study of people who use drugs in British Columbia, Canada. Harm Reduct J, 14(1), 39.

16. Khatri P, et al. (2023). Longitudinal assessment of depressive symptoms in patients receiving long-term fentanyl therapy. Pain Medicine, 24(3), 512-520.

17. Humphreys K, et al. (2018). Responding to the opioid crisis in North America and beyond: recommendations of the Stanford-Lancet Commission. Lancet, 391(10139), 2607-2608.

18. Larochelle MR, et al. (2019). Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality: A Cohort Study. Ann Intern Med, 170(6), 430-431.

19. Pardo B, et al. (2019). The future of fentanyl and other synthetic opioids. Int J Drug Policy, 66, 119-125.

20. Oquendo MA, Volkow ND. (2018). Suicide: A Silent Contributor to Opioid-Overdose Deaths. N Engl J Med, 378(17), 1567-1569.

21. McDonald R, Strang J. (2016). Are take-home naloxone programmes effective? Systematic review utilizing application of the Bradford Hill criteria. Addiction, 111(7), 1177-1187.

22. L.pez CR, S.nchez DM. (2023). Integrated treatment approach for chronic pain and depression: A randomized clinical trial. Pain and Psychiatric Care, 18(2), 178-186.

23. Dasgupta N, et al. (2018). Opioid Crisis: No Easy Fix to Its Social and Economic Determinants. Am J Public Health, 108(2), 182-186.

24. Volkow ND, Blanco C. (2021). The changing opioid crisis: development, challenges and opportunities. Mol Psychiatry, 26(1), 218-233.